Immunotherapy for Cancer: What It Is, Who Qualifies and How It Is Given

The bag hanging from the pole is clear, not the yellow or red some people picture when they hear “cancer treatment.” The woman in the recliner has a paperback open on her knee and a blanket someone warmed for her. When the nurse hooks up the line, she says something that sticks: “This one isn’t aimed at the tumor. It’s aimed at you.”

That sentence captures a shift that has quietly rewritten oncology over the past fifteen years. For most of the twentieth century, the strategy was to poison, burn or cut cancer out. The newer idea is to fix the surveillance system that let the cancer grow in the first place, and then step back and let it work.

The results have been genuinely remarkable for some people and frustratingly absent for others. Understanding why, and what the treatment actually involves week to week, is the difference between hope built on evidence and hope built on headlines.

What is immunotherapy for cancer, in plain terms?

Think of chemotherapy as a chemical fired at the tumor and radiation as a beam aimed at it. Immunotherapy does neither. It adjusts the body’s own security system so that immune cells, chiefly T cells, can find and destroy cancer cells they had been ignoring.

The word is an umbrella, not a single drug. Underneath it sit several very different approaches: antibodies that release the brakes on T cells, cells removed from a patient and re-engineered in a laboratory, signaling proteins that rally immune activity, viruses modified to infect tumor cells, and treatment vaccines that teach the immune system to recognize a specific cancer protein. What unites them, as the National Cancer Institute puts it, is that they treat cancer by helping the immune system do its job better rather than by attacking the tumor directly.

Two features follow from that mechanism. First, immunotherapy can keep working after the last infusion, because the immune system has memory. Second, its side effects look nothing like hair loss or nausea; they look like the immune system overreaching into healthy organs. Both features shape everything that follows in this article.

One honest caveat belongs up front. Immunotherapy is now a standard part of care for a growing list of cancers, including melanoma, lung, kidney, bladder and several blood cancers. For many other cancers it remains limited or is offered mainly through clinical trials. The label “immunotherapy” does not guarantee benefit, and a good oncology team will say so plainly.

Why doesn't the immune system stop cancer on its own?

The immune system does stop cancer, probably far more often than anyone realizes. Abnormal cells appear constantly and are cleared before they ever form a lump. The cancers that reach a diagnosis are, by definition, the ones that found a way around that surveillance.

They manage it in a handful of well-documented ways. Cancer cells are descended from a person’s own tissue, so they carry fewer of the “foreign” flags that make a virus-infected cell obvious. Many stop displaying the fragments of protein, called antigens, that T cells use for identification. Others learn to press the immune system’s built-in brakes: they coat themselves with a protein that plugs into a receptor on T cells and switches those T cells off, a mechanism the body normally uses to prevent autoimmune disease. Some tumors surround themselves with suppressive cells and signaling molecules that create a hostile neighborhood. A few simply wall themselves off so that immune cells cannot get in.

The everyday comparison is a burglar who looks like a resident, has learned the alarm code and has bribed the doorman. Each of those tricks is a target. Checkpoint inhibitors strip out the alarm code. Engineered T cells arrive with a new way to recognize the intruder. Cytokines and certain antibodies change the neighborhood. That mapping between how tumors hide and how each treatment works is the single most useful mental model for understanding this field, and it explains why one approach can succeed brilliantly in one cancer and do nothing in another.

What are the main types of cancer immunotherapy?

Because the treatments differ so much in how they are made and delivered, a side-by-side view helps more than a paragraph of prose.

Type	How it works	How it is usually given	Where it is commonly used
Immune checkpoint inhibitors	Antibodies that block the “off switch” tumors use on T cells	Intravenous infusion in an outpatient center, repeated in cycles; some newer forms as an injection under the skin	Melanoma, lung, kidney, bladder, head and neck, some lymphomas, tumors with certain DNA-repair defects
Monoclonal antibodies and bispecific T-cell engagers	Lab-made proteins that flag cancer cells or physically pull T cells to them	Intravenous infusion or injection under the skin	Several blood cancers and some solid tumors
CAR T-cell and other cell therapies	A patient’s own T cells are collected, re-engineered and multiplied, then returned	Single infusion after a short course of chemotherapy, with close monitoring	Certain leukemias, lymphomas and myeloma; a tumor-derived cell therapy exists for melanoma
Cytokines	Signaling proteins that stimulate immune cell growth and activity	Injection or infusion	Now used less often; historically in melanoma and kidney cancer
Oncolytic viruses	Modified viruses that infect and burst tumor cells, exposing antigens	Injection directly into a tumor	Certain melanoma lesions
Treatment vaccines and bacterial immunotherapy	Prime an immune response against a cancer antigen, or provoke local inflammation	Injection, or instillation into the bladder through a catheter	A cell-based vaccine for prostate cancer; early bladder cancer

Checkpoint inhibitors account for the great majority of immunotherapy given today, which is why the next section spends time on them. Cell therapies are far rarer but attract attention because they behave less like a medication and more like a living, one-time transplant of a new capability. Cleveland Clinic and the National Cancer Institute both describe these categories in detail in the references below.

How do checkpoint inhibitors work?

Every T cell carries molecular brakes. Without them, the immune system would attack the body’s own tissues, so evolution built in receptors that, when engaged, tell the T cell to stand down. These receptors are called immune checkpoints, and the best studied ones go by the abbreviations PD-1 and CTLA-4.

Tumors hijack this safety system. Many cancer cells produce the partner molecule, PD-L1, that fits into PD-1 like a key into a lock. When a T cell arrives to attack, the tumor presents the key, the brake engages, and the T cell goes quiet. The cancer effectively holds up a badge that says “nothing to see here.”

A checkpoint inhibitor is an antibody shaped to sit in that lock and block the handshake. With the brake released, T cells that were already present in the tumor but paralyzed can resume their work. This is why the treatment tends to succeed in cancers that are already “visible” to the immune system, meaning tumors with many mutations and many T cells trapped inside them. Melanoma and smoking-related lung cancer, which carry heavy mutation loads, respond more often than cancers with few mutations. Tumors with a faulty DNA-repair system, described as mismatch-repair deficient or microsatellite instability-high, respond regardless of where in the body they arise, which is why testing for that defect has become routine.

The same mechanism explains the downside. Releasing the brakes does not release them only inside the tumor. The National Cancer Institute notes that the resulting immune activity can spill over into the skin, gut, lungs, liver and hormone-producing glands, producing the distinctive side effects covered later.

What is CAR T-cell therapy and how is it different?

Most immunotherapy is a medication made in a factory. CAR T-cell therapy is a medication made from you.

The process begins with a procedure similar to blood donation, in which blood is drawn, T cells are filtered out and the rest is returned. Those T cells travel to a specialized laboratory where a gene is inserted that instructs them to build a new surface receptor, a chimeric antigen receptor, designed to lock onto a specific protein found on the cancer. The cells are then multiplied into the millions. The National Cancer Institute describes this manufacturing step as taking several weeks, during which some patients receive other treatment to keep the cancer in check.

Before the engineered cells are returned, a short course of chemotherapy clears space in the immune system so the new cells can expand. The infusion itself is a single event. What follows is not. Because the cells multiply inside the body and can trigger a surge of inflammatory signaling, patients are watched closely, often in the hospital or nearby. Cleveland Clinic advises that people stay within reach of their treatment center for about four weeks after infusion so that early complications can be caught quickly.

CAR T-cell therapies are currently approved for specific blood cancers, including certain leukemias, lymphomas and multiple myeloma, typically after other treatments have stopped working. A related approach, in which T cells are harvested from the tumor itself rather than engineered, has reached approval for advanced melanoma. Solid tumors more broadly remain the subject of active trials, largely because the physical barriers described earlier make it hard for infused cells to reach and persist inside them.

At what stage of cancer is immunotherapy used?

The honest answer has changed within a decade. When checkpoint inhibitors first arrived, they were reserved for people with advanced or metastatic disease who had exhausted other options. That is no longer the whole picture.

For several cancers, including many lung cancers, melanoma, kidney cancer and some bladder and head and neck cancers, immunotherapy is now a first choice for advanced disease, sometimes alone and sometimes alongside chemotherapy. It has also moved earlier. After surgery for higher-risk melanoma, lung, kidney and bladder cancers, a course of immunotherapy may be offered to reduce the chance of recurrence, a strategy called adjuvant treatment. Increasingly it is also given before surgery, as neoadjuvant therapy, on the reasoning that a tumor still in place gives the immune system a large target to learn from.

Where immunotherapy is generally not used is in the earliest-stage cancers that surgery alone is expected to handle, because adding a treatment with real risks offers little to gain. There are exceptions. Early bladder cancer confined to the lining has been treated for decades by instilling a bacterial preparation directly into the bladder, an immunotherapy that predates the modern era.

Stage is only one axis. The other is biology. A stage IV melanoma may be an excellent candidate while a stage II pancreatic cancer is not, because pancreatic cancer rarely responds to current immunotherapy outside trials. The same is true of most prostate cancers and many breast cancers, where immunotherapy has a role only in specific subtypes. The question to bring to your oncologist is therefore not “Am I at the right stage?” but “Does my cancer’s biology make this a reasonable option?”

Who qualifies for immunotherapy? Biomarkers, tests and health factors

Eligibility rests on three things: the cancer, the tumor’s molecular fingerprint and the person carrying it.

The cancer type and stage narrow the field, as the previous section described. Within that field, tissue from the biopsy is often tested for biomarkers. A pathologist may measure how much PD-L1 the tumor cells display; higher levels tend to predict a better chance of responding to checkpoint inhibitors, though people with low levels still sometimes respond. The tumor is checked for mismatch-repair deficiency or microsatellite instability, the DNA-repair defect that makes tumors of almost any origin responsive. Some laboratories also estimate tumor mutational burden. For cell therapies, the relevant test is whether the cancer carries the particular surface protein the engineered cells are built to recognize.

Then comes the person. Oncologists assess general fitness, often called performance status, because someone who is very frail may not tolerate the inflammatory side effects. Certain conditions call for caution rather than automatic exclusion: an existing autoimmune disease can flare when immune brakes are released, and people who have received an organ transplant face a risk of rejection because the medication that protects the transplant works in the opposite direction. Active serious infections and the need for ongoing immune-suppressing treatment are also weighed carefully.

When standard eligibility is not met, a clinical trial may be the route. Trials are not a last resort or a consolation prize; they are how every approved immunotherapy earned its place. The final decision is typically made by a multidisciplinary team, and it should feel like a conversation about goals rather than a verdict handed down.

How is immunotherapy given, and what does a treatment day look like?

For the majority of people, the setting is an outpatient infusion center, the same kind of room described in the opening of this article. A typical visit begins with blood tests, because the team needs to check the liver, kidneys and thyroid before each dose, and a conversation with a nurse or clinician about any new symptoms. If the results are acceptable, the antibody is delivered through a vein in the arm or through a port placed under the skin of the chest. Many people read, nap or work during the infusion, and most go home the same day.

Visits repeat in cycles, generally every few weeks on a schedule set by the treating team, and the pattern may continue for a defined period or until scans show the treatment is no longer helping. Some checkpoint inhibitors are now available as an injection under the skin, which shortens the chair time considerably; the choice between formulations belongs to the prescribing clinician.

Other routes exist for other types. Oncolytic viruses are injected straight into accessible tumors. Bacterial immunotherapy for early bladder cancer is instilled through a catheter and held in the bladder for a period before being passed. Cell therapies involve a hospital stay or daily monitoring nearby, as described earlier.

Between visits, people are usually given a wallet card or app that identifies them as receiving immunotherapy, a thermometer and a phone number that answers around the clock. Those tools matter more than they sound. Because the side effects can mimic ordinary illnesses, the key to safety is knowing to call rather than wait.

How long does immunotherapy take to work, and how is it monitored?

Immunotherapy tends to be slower than chemotherapy, and the way it shows up on scans can be confusing.

Chemotherapy kills dividing cells within days, so tumors often shrink quickly. An immune response has to be built: T cells must be released, multiply, travel into the tumor and begin their work. Oncologists usually wait through a couple of treatment cycles before ordering the first follow-up imaging. Even then, the first scan can look worse. A tumor flooded with immune cells may appear larger, a phenomenon called pseudoprogression that the National Cancer Institute describes. Distinguishing it from true growth depends on how the person feels, on blood markers and on a repeat scan a little later. This is one of the few situations in oncology where a clinician may reasonably say “let’s keep going” despite a discouraging picture.

Monitoring runs on two tracks. Imaging every few months assesses the cancer. Blood work at each visit watches for silent side effects, particularly in the thyroid, liver and adrenal glands, which can be disturbed without any early symptom.

The duration of treatment varies more than most people expect. Some protocols run for a fixed period and then stop even when the cancer remains controlled, on the evidence that the immune response can persist without further doses. Others continue as long as the treatment is helping and side effects are tolerable. Responses that appear after treatment ends, and responses that last for years after a set course, are among the properties that make this class of treatment unusual, though they are not the typical experience for everyone.

What is the downside of immunotherapy? Side effects explained honestly

The downside follows directly from the mechanism. Release the immune system’s brakes and it does not attack only the tumor.

The resulting problems are called immune-related adverse events, and clinicians often summarize them as “the -itis list”: dermatitis (rash and itch), colitis (diarrhea and abdominal pain), pneumonitis (cough and breathlessness), hepatitis (liver inflammation, often silent), and inflammation of hormone-producing glands. That last group deserves emphasis. When the thyroid, pituitary or adrenal glands are damaged, the effect can be permanent, leaving a person on lifelong hormone replacement. A rare form of diabetes can appear abruptly. Inflammation of the heart muscle is uncommon but serious. Most side effects are mild to moderate and manageable when caught early, but the National Cancer Institute is clear that they can appear at any point, including months after the last dose.

Cell therapies carry a different risk profile. As engineered T cells multiply, they can trigger cytokine release syndrome, a flood of inflammatory signals producing fever, low blood pressure and rapid heartbeat; the National Cancer Institute notes this typically begins within one to fourteen days of infusion. Some people also develop temporary neurological effects such as confusion, word-finding difficulty or tremor, which is why close observation is required.

Beyond the medical risks sit practical ones. Treatment is expensive, involves many appointments, and works for only a portion of people who receive it. Managing serious immune side effects usually means pausing treatment and taking medication that suppresses the immune system, which can feel like a step backward. None of this argues against immunotherapy. It argues for going in with clear eyes and a low threshold for picking up the phone.

Is immunotherapy stronger than chemotherapy?

The question assumes the two are competing versions of the same thing. They are not, and the word “stronger” hides more than it reveals.

Chemotherapy acts fast and broadly. It works in many cancers that current immunotherapy cannot touch, its effects are relatively predictable, and it has decades of evidence behind it. Its limitations are equally well known: it kills healthy dividing cells along with malignant ones, producing hair loss, nausea, mouth sores and low blood counts, and its benefit generally ends when the drug is stopped.

Immunotherapy acts slowly and selectively. In the cancers where it works, a proportion of people experience responses that persist long after treatment ends, something chemotherapy rarely achieves in advanced disease. In cancers where the immune system cannot see the tumor, it may do nothing at all. Its side effects spare the hair and the stomach lining but can inflame almost any organ.

In practice the two are frequently partners rather than rivals. For many lung cancers, the standard first treatment combines both, on the evidence that chemotherapy kills cells and releases antigens that help the immune system learn while the checkpoint inhibitor keeps the T cells switched on. Radiation is sometimes added for the same reason.

So which is “stronger”? For someone with advanced melanoma, immunotherapy has clearly outperformed the chemotherapy that preceded it. For someone with a cancer that lacks the biomarkers discussed earlier, chemotherapy may remain the more effective option. The strength of a treatment is only meaningful against a particular cancer in a particular person, which is exactly why biomarker testing before treatment matters so much.

Can you survive cancer with immunotherapy? What the evidence actually shows

Yes, some people do, and a few of those stories are extraordinary. People diagnosed with widespread melanoma in the early years of checkpoint inhibitors are alive today, years after their last infusion, with no detectable disease. Similar durable responses have been documented in lung cancer, kidney cancer, certain lymphomas and in tumors with the DNA-repair defect described earlier. The National Cancer Institute describes these long-lasting responses as one of the distinguishing features of the approach.

Honesty requires the other half of the picture. Durable responses are the minority outcome in most cancers, not the rule. For many people, immunotherapy slows the disease or adds months of good-quality life rather than eliminating it. For others it does not work at all, and precious time is spent discovering that. Whether a durable response amounts to a “cure” is a word most oncologists still use cautiously, because the follow-up data for these treatments span years rather than the decades available for surgery.

What the evidence does support is a shift in expectations for specific cancers. Some advanced cancers that were once considered rapidly fatal now have a meaningful proportion of long-term survivors, and that shift is real, reproducible and reflected in treatment guidelines worldwide.

The most useful response to the survival question is a more specific one: for my cancer, with my biomarkers, what does the evidence show about the chance of response, how long responses tend to last, and what the realistic goal of treatment is? An oncology team that answers that question directly, with numbers where numbers exist and with candor where they do not, is offering something more valuable than reassurance.

When to see a doctor during immunotherapy: red-flag symptoms

People receiving immunotherapy are usually told something that sounds counterintuitive: do not tough it out. Symptoms that would be minor for anyone else can signal inflammation that is far easier to treat early than late. Any new or worsening symptom should be reported to the treating team the same day, using the number provided at the start of treatment.

Call promptly for any of the following:

• Fever or chills, especially in the weeks after a cell-therapy infusion
• New or worsening cough, shortness of breath or chest pain
• Diarrhea that is more frequent than usual for you, watery, or contains blood or mucus, or severe abdominal pain
• Yellowing of the skin or eyes, dark urine, or pain under the right ribs
• Persistent headache, vision changes, or unusual dizziness on standing
• Extreme thirst, frequent urination or profound fatigue, which can signal a hormonal or blood-sugar problem
• A rash that blisters, peels or involves the mouth or eyes
• Confusion, difficulty speaking, tremor or seizure, particularly after CAR T-cell therapy
• A racing or irregular heartbeat, or swelling of the legs

Seek emergency care without waiting for a callback for chest pain, severe breathing difficulty, fainting, a seizure, or sudden confusion. Anyone treating you in an emergency department should be told that you are receiving immunotherapy and shown your alert card, because the symptoms can look like an infection or a routine stomach bug and be managed incorrectly if the context is missing.

Two more habits protect against trouble. Check with the oncology team before starting any new medication, supplement or over-the-counter remedy, since some can mask a fever or interact with treatment. And keep every scheduled blood test, even when feeling well; the glands most often affected rarely announce themselves early.

What matters most: questions to ask your oncology team

Having read this far, one opinion is worth stating plainly. The single most consequential moment in an immunotherapy journey is not the first infusion. It is the biopsy report, because whether the tumor is tested for the right biomarkers determines whether immunotherapy is even on the table. Asking about testing is not second-guessing your doctors; it is participating in the decision.

The second most consequential thing is a shared, honest understanding of the goal. “Control for as long as possible,” “reduce the chance of recurrence after surgery” and “aim for a durable remission” are three different plans with different trade-offs, and the right side-effect tolerance depends on which one you are pursuing.

Questions that tend to produce useful answers:

• Has my tumor been tested for PD-L1, mismatch-repair deficiency and other markers relevant to immunotherapy, and what did they show?
• Is immunotherapy a standard option for my cancer at this stage, or would it be offered through a clinical trial?
• What is the realistic goal of this treatment for me, and how will we know whether it is working?
• How will the treatment be given, how often, and for how long is it planned?
• Which side effects should I watch for, and exactly whom do I call at 2 a.m.?
• How might my other health conditions, including any autoimmune disease, affect the risks?
• If the first scan looks worse, how will you decide whether to continue?

Bring a second person to the appointment if you can, and ask for the answers in writing. Immunotherapy is a field where the evidence is genuinely encouraging, genuinely incomplete and moving quickly. The people who navigate it best are not the most optimistic. They are the best informed, and they treat their care team as partners in a decision rather than as the source of a decree.

Frequently asked questions

At what stage of cancer is immunotherapy used?

Immunotherapy is most often used for advanced or metastatic cancer, but for several cancers it is now also given after surgery to reduce recurrence risk or before surgery to shrink a tumor. It is rarely used for the earliest-stage cancers that surgery alone is expected to handle. Whether it is appropriate depends less on stage number than on the cancer type and its biomarkers, which is why tumor testing comes first.

What is the downside of immunotherapy?

The main downside is that an activated immune system can attack healthy tissue, causing inflammation of the skin, bowel, lungs, liver or hormone glands, sometimes months after treatment ends. Damage to the thyroid or adrenal glands can be permanent. Cell therapies can trigger cytokine release syndrome and temporary neurological effects. Immunotherapy also works for only a portion of people, so time and cost can be spent without benefit.

Can you survive cancer with immunotherapy?

Some people do, including individuals with advanced melanoma and lung cancer who remain disease-free years after finishing treatment. Those durable responses are a real and distinctive feature of immunotherapy, but they are the minority outcome in most cancers. For many people the benefit is slowing the disease rather than eliminating it, and for others there is no response. Your own outlook depends on your specific cancer and biomarkers.

Is immunotherapy stronger than chemotherapy?

Neither is universally stronger; they work by different mechanisms and suit different cancers. Chemotherapy acts fast and broadly but its effect ends when it stops. Immunotherapy acts slowly and selectively but can produce responses that last long after treatment. In cancers such as advanced melanoma it has outperformed older chemotherapy; in cancers lacking immune biomarkers chemotherapy may be more effective. The two are frequently combined.

How is immunotherapy given?

Most immunotherapy is given as an intravenous infusion in an outpatient center, repeated in cycles every few weeks after blood tests confirm the liver, kidneys and thyroid are functioning normally. Some antibodies are now injected under the skin. Cell therapies involve collecting a patient’s T cells, engineering them over several weeks, then returning them in a single monitored infusion. Bladder immunotherapy is instilled through a catheter.

How long does immunotherapy take to work?

Immunotherapy usually works more slowly than chemotherapy because an immune response must be built rather than delivered. Oncologists typically wait through a couple of treatment cycles before the first follow-up scan. An early scan can even look worse because the tumor fills with immune cells, a pattern called pseudoprogression. How you feel, blood markers and a repeat scan together show whether the treatment is helping.

Who is not a good candidate for immunotherapy?

People whose cancers lack the relevant biomarkers, or whose cancer type rarely responds, are unlikely to benefit outside a clinical trial. Caution is also needed for people with active autoimmune disease, which can flare when immune brakes are released, and for organ transplant recipients, because immunotherapy can trigger rejection. Very poor general fitness, active serious infection and ongoing immune-suppressing treatment are also weighed carefully by the team.

What is CAR T-cell therapy?

CAR T-cell therapy takes a patient’s own T cells, genetically modifies them in a laboratory to carry a receptor that recognizes a protein on the cancer, multiplies them, and returns them as a single infusion after a short course of chemotherapy. It is currently approved for certain leukemias, lymphomas and myeloma. Because the cells expand inside the body, close monitoring for about four weeks afterward is standard.

Does immunotherapy cause hair loss?

Checkpoint inhibitors generally do not cause hair loss, because they do not target rapidly dividing cells the way chemotherapy does. Their side effects instead come from immune activity against healthy organs, producing rash, diarrhea, cough, liver inflammation or hormone changes. If immunotherapy is combined with chemotherapy, as it often is for lung cancer, hair loss may occur from the chemotherapy component. Your team can tell you what to expect from your specific regimen.

What symptoms should I report immediately during immunotherapy?

Report fever, new cough or breathlessness, diarrhea that is more frequent than usual or bloody, severe abdominal pain, yellowing skin, persistent headache or vision changes, extreme thirst, a blistering rash, confusion or difficulty speaking, and any racing or irregular heartbeat. Seek emergency care for chest pain, severe breathing difficulty, fainting or seizure. Tell any emergency clinician you are receiving immunotherapy, because these symptoms can be mistaken for ordinary illness.

References

• MedlinePlus: Cancer Immunotherapy
• Cleveland Clinic: Immunotherapy
• Cleveland Clinic: CAR T-Cell Therapy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.